VanEck Pharmaceutical ETF
PPH
142 hedge funds and large institutions have $545M invested in VanEck Pharmaceutical ETF in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 17 closing their positions.
72% more call options, than puts
Call options by funds: $1.2M | Put options by funds: $694K
23% more capital invested
Capital invested by funds: $442M → $545M (+$103M)
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
1.75% more ownership
Funds ownership: 73.85% → 75.6% (+1.7%)
1% more funds holding
Funds holding: 140 → 142 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$61.7M |
| 2 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
+$8.74M |
| 3 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$8M |
| 4 |
AWC
Adamsbrown Wealth Consultants
Wichita,
Kansas
|
+$7.03M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$13.9M |
| 2 |
BC
Bricktown Capital
Detroit,
Michigan
|
-$5.9M |
| 3 |
SA
Sanctuary Advisors
Indianapolis,
Indiana
|
-$3.96M |
| 4 |
PAG
Private Advisory Group
Redmond,
Washington
|
-$3.07M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.41M |
PPH Hedge Fund Activity: Q3 2024 in Review
142 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2024, worth a combined $545M — up 23% from $442M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PPH positions and 17 closed out — a net gain of 2 holders — while 52 added to existing stakes and 46 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $61.7M. The largest seller was JP Morgan Chase, cutting an estimated $13.9M.
- 142 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2024, up from 140 in Q2 2024.
- Funds reported $545M of VanEck Pharmaceutical ETF stock for Q3 2024, up 23% quarter-over-quarter.
- 19 funds opened new VanEck Pharmaceutical ETF positions in Q3 2024 and 17 closed out, a net change of +2 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q3 2024 was Goldman Sachs, an estimated $61.7M added.
- The largest VanEck Pharmaceutical ETF seller in Q3 2024 was JP Morgan Chase, an estimated $13.9M sold.
Based on aggregated 13F filings for Q3 2024.